Rakovina Therapeutics Inc. (RKVTF)
| Market Cap | 5.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.83M |
| Shares Out | n/a |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,419 |
| Average Volume | 57,986 |
| Open | 0.0388 |
| Previous Close | 0.0377 |
| Day's Range | 0.0383 - 0.0388 |
| 52-Week Range | 0.0289 - 10.0000 |
| Beta | -0.32 |
| RSI | 47.89 |
| Earnings Date | Aug 29, 2025 |
About Rakovina Therapeutics
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]
News
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
$3 Million Lead Order from Strategic Investors Supports Bold Transformation $3 Million Lead Order from Strategic Investors Supports Bold Transformation
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer ...
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artif...
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Data highlights novel PARP1 and ATR inhibitors with progress toward next-ge...
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum
VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics and Variational AI Strengthen Partnership
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collaborations Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collabo...
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response t...
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damag...
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligenc...
Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation
VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on...
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical company focused on the development of new cance...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered...
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to a...
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit
VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer ther...
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new ...
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million
VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new ...
Rakovina Therapeutics Announces Private Placement Offering
The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering The Company has received initial commitments totaling over $800,000 from st...
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer ther...
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer ther...
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer ther...
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform
Company to present initial results of this research at the Society for Neuro-Oncology Annual Meeting in November Company to present initial results of this research at the Society for Neuro-Oncology A...